Dr Reddy's Labs launches Abiraterone Acetate Tablets in US
Dr Reddy's Abiraterone Acetate is available in 250 mg tablets in bottle count sizes of 120.
Hyderabad and Princeton: Dr Reddy's Laboratories Ltd. has announced the launch of Abiraterone Acetate Tablets USP, 250 mg, a therapeutic equivalent generic version of Zytiga® (abiraterone acetate) approved by the U.S. Food and Drug Administration (USFDA).
The Zytiga® brand and the generic market had U.S. sales of approximately $454 million MAT for the most recent twelve months ending in March 2020 according to IQVIA Health*.
Dr Reddy's Abiraterone Acetate is available in 250 mg tablets in bottle count sizes of 120.
Zytiga® (abiraterone acetate) is a trademark of Johnson & Johnson corporation.
Dr Reddy's Laboratories Ltd. is an integrated pharmaceutical company headquartered in Hyderabad, committed to providing affordable and innovative medicines for healthier lives.
Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology.
The Company's markets include – USA, India, Russia & CIS countries, and Europe.
Read also: CDSCO reviewing Cipla, Dr Reddys, others applications for Remdesivir on priority: Health Ministry
